|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007131,
umls-concept:C0008838,
umls-concept:C0015133,
umls-concept:C0016360,
umls-concept:C0205210,
umls-concept:C0205420,
umls-concept:C0282460,
umls-concept:C0439807,
umls-concept:C0456599,
umls-concept:C0684224,
umls-concept:C0817096,
umls-concept:C1511237,
umls-concept:C1522449,
umls-concept:C1550436,
umls-concept:C1705509
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1993-7-19
|
|
pubmed:abstractText |
To assess the response rate, median and long-term survival of patients (pts) with locally advanced, initially inoperable non-small cell lung cancer (NSCLC) treated on a phase II study of radical thoracic radiotherapy (TRT) and concurrent radiosensitizing chemotherapy.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0360-3016
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
469-78
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:8390421-Adult,
pubmed-meshheading:8390421-Aged,
pubmed-meshheading:8390421-Aged, 80 and over,
pubmed-meshheading:8390421-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8390421-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:8390421-Cisplatin,
pubmed-meshheading:8390421-Combined Modality Therapy,
pubmed-meshheading:8390421-Etoposide,
pubmed-meshheading:8390421-Female,
pubmed-meshheading:8390421-Fluorouracil,
pubmed-meshheading:8390421-Humans,
pubmed-meshheading:8390421-Lung Neoplasms,
pubmed-meshheading:8390421-Male,
pubmed-meshheading:8390421-Middle Aged,
pubmed-meshheading:8390421-Retrospective Studies,
pubmed-meshheading:8390421-Survival Analysis,
pubmed-meshheading:8390421-Survival Rate,
pubmed-meshheading:8390421-Thorax
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Report of phase II trial of concurrent chemoradiotherapy with radical thoracic irradiation (60 Gy), infusional fluorouracil, bolus cisplatin and etoposide for clinical stage IIIB and bulky IIIA non-small cell lung cancer.
|
|
pubmed:affiliation |
Department of Medical Oncology, Fox Chase Cancer Center (FCCC), Philadelphia, PA 19111.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase II
|
